ArticleBMC health services research2026
Cancer care in Pakistan: a national survey of infrastructure, diagnostic capacity, therapeutic access, and workforce perspectives.
Article in BMC health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPakistan, a lower-middle-income country of some 241 million people, faces a rising cancer burden - an estimated 185,748 new cancer cases and 118,631 cancer deaths in 2022 - that is served by a heterogeneous and largely uncoordinated mix of public, private for-profit, philanthropic, and Atomic Energy Commission cancer facilities. Nationally representative data on oncology infrastructure, diagnostic capacity, therapeutic access, and workforce conditions remain limited. We surveyed oncology professionals to describe, from their perspective, the capabilities of their institutions and their own working conditions.
methodsA cross-sectional survey was completed by 111 oncology professionals practising across ten cities in four provinces between July and September 2025. A structured questionnaire captured institutional infrastructure, diagnostic and molecular testing, multidisciplinary practice, therapeutic availability, supportive services, research activity, financial constraints, and workforce perspectives. Data were analysed descriptively with the individual respondent as the unit of analysis. Institutional sector (private, government, or Atomic Energy Cancer Hospital) was assigned post hoc from each respondent's known institutional affiliation and compared using the χ² test with Freeman-Halton exact confirmation.
resultsRespondents comprised radiation/clinical (55.9%), medical (25.2%), and surgical (18.9%) oncologists; 81.1% practised in academic teaching hospitals, and two cities (Karachi and Lahore) accounted for 66.6% of respondents. Computed tomography was reported by 99.1% and positron-emission tomography by 57.7%; next-generation sequencing was reported by 61.3%, although most of these respondents indicated that fewer than half of their patients could afford it. Immunotherapy was reported at 76.6% of settings and dedicated palliative care at 39.6%. Financial barriers were reported by 94.6% of respondents, and only 27.9% were satisfied with their compensation. In exploratory sector comparisons, radiotherapy infrastructure was concentrated in Atomic Energy hospitals, whereas reported resource shortages rose from private (47%) through Atomic Energy (73%) to government (92%) settings.
conclusionsRespondents described an oncology system with foundational strengths concentrated in a few urban academic centres, alongside limited advanced diagnostics, sparse supportive care, and pervasive financial barriers. As what is, to our knowledge, the first structured national survey of its kind, and a descriptive, self-reported one, these findings map perceived gaps rather than verified service levels or patient outcomes, and are intended to provide a baseline that informs - not substitutes for - formal national cancer-capacity assessment and planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.